Last update June 19, 2026

克林霉素

Compatible

Safe product and/or breastfeeding is the best option.

A lincosamide-derived antibiotic active against many Gram-positive bacteria (staphylococci, streptococci, Clostridium), as well as some anaerobes (Bacteroides fragilis) and parasites (Plasmodium, Toxoplasma). Administered orally, intramuscularly or intravenously in 3 to 4 daily doses. Topical application to the skin and vaginally.

It is excreted in breast milk in small, clinically insignificant amounts (van Wattum 2019, Zhang 1997, Matsuda 1984, Stéen 1982, Smith 1975) and no problems have been observed in infants whose mothers were taking it, apart from occasional gastroenterocolitis due to an alteration in the gut microbiota, which resolves within a few days of finishing treatment. (Mann 1980)
Clindamycin may be administered intravenously for the treatment of severe acute mastitis, with no side effects in the infant (Maier 2021), although it is a second-line treatment. (Mitchel 2022)

Bear in mind the possibility of transient gastroenteritis due to changes in the gut microbiota in infants whose mothers are taking antibiotics. (Ito 1993)

DERMATOLOGICAL AND VAGINAL USE:
The low dose and poor plasma absorption of most topical dermatological preparations make it unlikely that significant amounts will pass into breast milk. Less than 5% of topical clindamycin (Yagui 2024, Ly 2023, van Hoogdalem 1998, Eller 1998, Barza 1982), 10% of the vaginal cream and 30% of the vaginal ovule (Borin 1999, 1995 and 1990) pass into plasma.
Do not apply to the breast to prevent the infant from ingesting it; if necessary, apply after a feed and clean thoroughly with water before the next one. It is advisable to avoid applying creams, gels and other topical products containing paraffin (mineral oil) to the nipple so that the infant does not absorb them. (Concin 2008, Noti 2003)

Clindamycin is an antibiotic authorised for use in paediatrics, including in preterm infants.
Expert authors consider the use of this medication during breastfeeding to be safe. (Mitchel 2022, Hale, van Wattum 2019, Saito 2018, Briggs 2015, Schaefer 2015, Butler 2014, Amir 2014 and 2011, Kong 2013, Mitrano 2009, Spencer 2008, Nahum 2006, Chin 2001)  American Academy of Paediatrics: medication usually compatible with breastfeeding. (AAP 2001)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Tradenames

Main tradenames from several countries containing 克林霉素 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 425 daltons
Protein Binding 94 %
VD 2 l/Kg
pKa 7.45 -
Tmax 0.75 - 1 hours
2.4 hours
M/P ratio 0.5 -
Theoretical Dose 0.2 - 0.47 mg/Kg/d
Relative Dose 0.6 - 5 %
Ped.Relat.Dose 1 - 5 %

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. Yaghi M, McMullan P, Truong TM, Rothe M, Murase J, Grant-Kels JM. Safety of dermatologic medications in pregnancy and lactation: An update-Part II: Lactation. J Am Acad Dermatol. 2024 Oct;91(4):651-668. Abstract
  3. Ly S, Kamal K, Manjaly P, Barbieri JS, Mostaghimi A. Treatment of Acne Vulgaris During Pregnancy and Lactation: A Narrative Review. Dermatol Ther (Heidelb). 2023 Jan;13(1):115-130. Abstract Full text (link to original source)
  4. Mitchell KB, Johnson HM, Rodríguez JM, Eglash A, Scherzinger C, Zakarija-Grkovic I, Cash KW, Berens P, Miller B; Academy of Breastfeeding Medicine. Academy of Breastfeeding Medicine Clinical Protocol #36: The Mastitis Spectrum, Revised 2022. Breastfeed Med. 2022 May;17(5):360-376. Abstract Full text (link to original source)
  5. Maier JT, Daut J, Schalinski E, Fischer-Medert T, Hellmeyer L. Severe Lactational Mastitis With Complicated Wound Infection Caused by Streptococcus pyogenes. J Hum Lact. 2021 Feb;37(1):200-206. Abstract
  6. van Wattum JJ, Leferink TM, Wilffert B, Ter Horst PGJ. Antibiotics and lactation: An overview of relative infant doses and a systematic assessment of clinical studies. Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):5-17. Abstract
  7. Saito M, Gilder ME, McGready R, Nosten F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018 Nov;17(11):1129-1144. Abstract Full text (link to original source) Full text (in our servers)
  8. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  9. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015
  10. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014 Mar;70(3):417.e1-10; quiz 427. Abstract
  11. Amir LH; Academy of Breastfeeding Medicine Protocol Committee. ABM Clinical Protocol #4: Mastitis, Revised March 2014. Breastfeed Med. 2014;9(5):239-243. Abstract Full text (link to original source) Full text (in our servers)
  12. Amir LH. y el Comité de protocolos de la Academy of Breastfeeding Medicine. Protocolo clínico de la ABM n.o 4: Mastitis, modi cado en marzo de 2014. Breastfeed Med. 2014;9(5):239-243. Abstract Full text (link to original source) Full text (in our servers)
  13. Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Drugs. 2013 Jun;73(8):779-87. Abstract
  14. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract
  15. Mitrano JA, Spooner LM, Belliveau P. Excretion of antimicrobials used to treat methicillin-resistant Staphylococcus aureus infections during lactation: safety in breastfeeding infants. Pharmacotherapy. 2009 Sep;29(9):1103-9. Abstract
  16. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  17. Spencer JP. Management of mastitis in breastfeeding women. Am Fam Physician. 2008 Abstract Full text (link to original source) Full text (in our servers)
  18. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006 Abstract
  19. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
  20. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  21. Chin KG, McPherson CE 3rd, Hoffman M, Kuchta A, Mactal-Haaf C. Use of anti-infective agents during lactation: Part 2--Aminoglycosides, macrolides, quinolones, sulfonamides, trimethoprim, tetracyclines, chloramphenicol, clindamycin, and metronidazole. J Hum Lact. 2001 Feb;17(1):54-65. Abstract
  22. Borin MT, Ryan KK, Hopkins NK. Systemic absorption of clindamycin after intravaginal administration of clindamycin phosphate ovule or cream. J Clin Pharmacol. 1999 Abstract
  23. van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998 Abstract
  24. Zhang Y, Zhang Q, Xu Z. [Tissue and body fluid distribution of antibacterial agents in pregnant and lactating women]. Zhonghua Fu Chan Ke Za Zhi. 1997 Abstract
  25. Borin MT, Powley GW, Tackwell KR, Batts DH. Absorption of clindamycin after intravaginal application of clindamycin phosphate 2% cream. J Antimicrob Chemother. 1995 Abstract
  26. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  27. Borin MT. Systemic absorption of clindamycin following intravaginal application of clindamycin phosphate 1% cream. J Clin Pharmacol. 1990 Abstract
  28. Eller MG, Smith RB, Phillips JP. Absorption kinetics of topical clindamycin preparations. Biopharm Drug Dispos. 1989 Sep-Oct;10(5):505-12. Abstract
  29. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol. 1984;5(2):57-60. Abstract
  30. Barza M, Goldstein JA, Kane A, Feingold DS, Pochi PE. Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol. 1982 Aug;7(2):208-14. Abstract
  31. Stéen B, Rane A. Clindamycin passage into human milk. Br J Clin Pharmacol. 1982 Abstract Full text (link to original source) Full text (in our servers)
  32. Mann CF. Clindamycin and breast-feeding. Pediatrics. 1980 Abstract
  33. Smith JA, Morgan JR, Rachlis AR, Papsin FR. Clindamycin in human breast milk. Can Med Assoc J. 1975 Abstract Full text (in our servers)

Total visits

4,442

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM